Therapeutic effect of induction therapy including nab-paclitaxel followed by surgical resection for the patients with locally advanced non-small-cell lung cancer.

Publisher: BioMed Central Country of Publication: England NLM ID: 101265113 Publication Model: Electronic Cited Medium: Internet ISSN: 1749-8090 (Electronic) Linking ISSN: 17498090 NLM ISO Abbreviation: J Cardiothorac Surg Subsets: MEDLINE

Original Publication: [London] : BioMed Central, 2006-

Carcinoma, Non-Small-Cell Lung*/therapy ; Carcinoma, Non-Small-Cell Lung*/drug therapy ; Carcinoma, Non-Small-Cell Lung*/pathology ; Paclitaxel*/therapeutic use ; Paclitaxel*/administration & dosage ; Lung Neoplasms*/drug therapy ; Lung Neoplasms*/pathology ; Lung Neoplasms*/therapy ; Albumins*/therapeutic use ; Albumins*/administration & dosage ; Induction Chemotherapy*/methods; Humans ; Male ; Female ; Middle Aged ; Aged ; Neoplasm Staging ; Pneumonectomy/methods ; Treatment Outcome

Background: Lung cancer is associated with a high mortality rate worldwide. Non-small-cell lung cancer (NSCLC) is a major subtype of lung cancer. Carboplatin (CBDCA) plus nab-paclitaxel (PTX) has become a standard treatment for advanced unresectable NSCLC. However, treatment with nab-PTX has not been established as a standard therapy for resectable locally advanced (LA)-NSCLC.
Methods: We conducted a comprehensive study involving consecutive patients with locally advanced NSCLC who underwent induction therapy including nab-PTX followed by surgical resection. Fifteen patients with locally advanced NSCLC underwent induction therapy including nab-PTX followed by surgical resection. Concurrent chemoradiotherapy (CRT) consisted of weekly administration of nab-PTX (50 mg/m ² ) plus CBDCA (area under the plasma concentration time curve (AUC) 2) and thoracic radiotherapy (50 Gy/25 fractions).
Results: The clinical stages were as follows: IIB (n =1), IIIA (n =12), and IIIC (n =2). Downstaging was observed in 73% (11/15) of patients on comparison with the clinical stage before concurrent CRT. Adverse drug reactions were observed in seven patients. Complete resection was performed in all patients. The re-evaluated pathological stage after pretreatment was diagnosed as stage 0 in three patients, stage IA1 in six, stage IA2 in one, and stage IIIA in five. The pathological effects of previous therapy were as follows: Ef3 (n =3), Ef2 (n =9), and Ef1a (n =3).
Conclusion: The therapeutic effect of induction therapy including nab-PTX was promising. Induction CRT, including nab-PTX, followed by resection, may be a viable alternative treatment option for locally advanced NSCLC.
(© 2024. The Author(s).)

Transl Lung Cancer Res. 2023 Jan 31;12(1):141-149. (PMID: 36762056)
JTO Clin Res Rep. 2022 Jul 31;3(9):100384. (PMID: 36118131)
Lancet Healthy Longev. 2021 Dec;2(12):e791-e800. (PMID: 36098037)
Case Rep Oncol. 2014 Oct 23;7(3):700-10. (PMID: 25493083)
Ann Oncol. 2018 Aug 1;29(8):1853-1860. (PMID: 29982279)
Lung Cancer. 2021 Apr;154:76-83. (PMID: 33631448)
CA Cancer J Clin. 2018 Nov;68(6):394-424. (PMID: 30207593)
Clin Lung Cancer. 2017 Jan;18(1):100-103. (PMID: 28341108)
Cancer Res Treat. 2024 Jan 16;:. (PMID: 38228082)
Ann Thorac Cardiovasc Surg. 2022 Apr 20;28(2):111-120. (PMID: 34776459)
Lung Cancer. 2014 May;84(2):151-5. (PMID: 24602394)
Clin Cancer Res. 2006 Feb 15;12(4):1317-24. (PMID: 16489089)
Oncoimmunology. 2021 Oct 25;10(1):1996000. (PMID: 34712513)
J Clin Oncol. 2010 Apr 10;28(11):1843-9. (PMID: 20231678)
J Clin Oncol. 2022 Apr 20;40(12):1301-1311. (PMID: 35108059)
Nat Commun. 2021 Aug 19;12(1):5045. (PMID: 34413300)
Nat Med. 2021 Mar;27(3):504-514. (PMID: 33603241)
J Natl Compr Canc Netw. 2012 May;10(5):599-613. (PMID: 22570291)
Anticancer Res. 2016 Aug;36(8):4243-7. (PMID: 27466539)
JAMA Oncol. 2023 Oct 1;9(10):1348-1355. (PMID: 37535377)
Ann Thorac Surg. 2018 Oct;106(4):1018-1024. (PMID: 29890150)
Anticancer Res. 2016 May;36(5):2385-9. (PMID: 27127147)
J Clin Oncol. 2012 Jun 10;30(17):2055-62. (PMID: 22547591)
J Natl Cancer Inst. 2007 Mar 21;99(6):442-50. (PMID: 17374834)
Lancet. 2007 Jun 9;369(9577):1929-37. (PMID: 17544497)
J Thorac Dis. 2014 Jun;6(6):574-7. (PMID: 24976973)
Lung Cancer. 2018 Nov;125:136-141. (PMID: 30429011)
Immunity. 2013 Jul 25;39(1):1-10. (PMID: 23890059)
J Natl Cancer Inst. 1994 May 4;86(9):673-80. (PMID: 8158698)

Keywords: Induction therapy; NSCLC; Surgical resection; Therapeutic effect

P88XT4IS4D (Paclitaxel)
0 (130-nm albumin-bound paclitaxel)
0 (Albumins)

Date Created: 20240705 Date Completed: 20240705 Latest Revision: 20240708

20240708

PMC11225121

10.1186/s13019-024-02955-w

38970073